Loading dashboard...
Peptide Assistant
Online
AI can make mistakes. Verify important medical data.
Press Enter to send
G
Medical Engine
Guest Account
AI can make mistakes. Verify important medical data.
Press Enter to send
Medical Engine
Guest Account
Loading dashboard...
Empathy vs Insight. Comparing the neurobiological and therapeutic profiles of MDMA and Psilocybin.
MDMA is an empathogen that primarily works by flooding the brain with serotonin and oxytocin while quieting the amygdala. This "optimal arousal zone" allows patients to revisit trauma without being re-traumatized by fear.
MDMA is considered 'directive'—therapists can actively engage the patient in trauma processing.
Key focus: PTSD and interpersonal connection.
Psilocybin is a classic psychedelic that disrupts the Default Mode Network (DMN), facilitating "ego dissolution" and global neural crosstalk. This allows for deep existential insights and a shift in fundamental perspectives.
Psilocybin is 'non-directive'—the patient is often inward-focused (eyeshades and music).
Key focus: Depression, end-of-life anxiety, and habit dissolution.
MDMA is an amphetamine derivative and carries higher cardiovascular stress and neurotoxicity risks (at high/frequent doses) compared to psilocybin. Psilocybin is physically very safe but carries higher psychological risk for those predisposed to psychosis.
Serotonin depletion can lead to a mood dip 48-72 hours post-session.
Virtually no known lethal dose, but "bad trips" can be psychologically destabilizing without support.
"MDMA heals the heart so the mind can speak; Psilocybin opens the mind so the soul can see. Choosing the right tool depends on whether the barrier is fear-based trauma or existential stagnation."